Pyxis oncology (nas: pyxs)
Pyxis Oncology (NAS: PYXS) is a biotechnology company dedicated to creating innovative therapeutics aimed at targeting challenging cancers and enhancing patient quality of life.
Pyxis oncology (nas: pyxs) Overview
Pyxis oncology (nas: pyxs) Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
IPO | 10/8/2021 | ||||
Series B | 3/5/2021 | ||||
Series A | 7/12/2019 |
Pyxis oncology (nas: pyxs) 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Pyxis oncology (nas: pyxs) Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Pyxis oncology (nas: pyxs) News
Leerink Partnrs Lowers Earnings Estimates for Pyxis Oncology
MarketBeatOctober 18, 2024
Millennium Management LLC Grows Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS)
MarketBeatOctober 13, 2024
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Buy" from Analysts
MarketBeatSeptember 29, 2024
Blue Owl Capital Holdings LP Purchases New Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS)
MarketBeatSeptember 28, 2024
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
MorningstarSeptember 25, 2024
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by Bank of New York Mellon Corp
MarketBeatSeptember 22, 2024
Pyxis Oncology (NASDAQ:PYXS) Receives "Outperform" Rating from Royal Bank of Canada
MarketBeatSeptember 19, 2024
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of "Buy" from Analysts
MarketBeatSeptember 4, 2024